Addressing Anti-Competitive Health Care Contract Clauses Act

Bill Number: H.R. 3020
Origin Chamber: House
Congress: 119th Congress, Session 1
Policy Area: Health
Status: Introduced
Latest Action: 2025-04-24: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Last Updated: 2025-05-20T14:46:44Z

AI-Generated Summary

Purpose of the Legislation

The "Addressing Anti-Competitive Health Care Contract Clauses Act" (H.R. 3020) aims to investigate how certain restrictive clauses in contracts between health insurers and health care providers affect competition in the health care industry. It directs the Government Accountability Office (GAO) to study these clauses' impacts on prices, access to care, and industry consolidation, while reviewing enforcement efforts by federal agencies and suggesting ways to strengthen antitrust protections.

Key Provisions

GAO Study Mandate: Within 18 months of enactment, the GAO's Comptroller General must conduct a study in coordination with the Federal Trade Commission (FTC) and the Department of Justice's (DOJ) Antitrust Division. The study covers:
Effects of specific anticompetitive clauses (anti-steering, anti-tiering, all-or-nothing, and gag clauses) on health care consolidation, consumer prices for medical services, and access to care.
A list of all FTC and DOJ actions (direct or indirect) related to these clauses in insurer-provider contracts.
An assessment of whether the FTC and DOJ have sufficient resources and capabilities to enforce federal antitrust laws against these clauses.
Recommendations for legislative or administrative changes to enhance enforcement if needed.
Report Submission: The GAO must submit the study results to key congressional committees, including House committees on Energy and Commerce, Ways and Means, Education and Workforce, and Judiciary; and Senate committees on Health, Education, Labor, and Pensions, and Judiciary.
Definitions of Key Terms:
Anti-steering clause: A contract provision that limits an insurer's ability to guide patients toward lower-cost or preferred providers, such as by offering incentives.
Anti-tiering clause: Restricts an insurer from creating or adjusting "tiered network plans" (systems that group providers into levels with different costs or access rules) or requires all providers from a group to be in the same tier.
All-or-nothing clause: Forces an insurer to include all providers from a group in a network or sign extra contracts with affiliates as a condition of contracting.
Gag clause: Prohibits sharing pricing or quality information (e.g., negotiated rates, fees, or out-of-pocket costs) with patients, other providers, government entities, or potential enrollees.

Significant Changes to Existing Law

This bill introduces no direct amendments to current laws. Instead, it creates a one-time investigative requirement for the GAO, building on existing federal antitrust laws (which prohibit anticompetitive practices) by mandating an evaluation of their application to health care contracts. It does not ban or regulate the clauses itself but could inform future enforcement or reforms.

Potential Impacts

On Government Agencies: The GAO will gain a new workload for the study, while the FTC and DOJ may face scrutiny of their resources, potentially leading to increased funding or authority requests. This could strengthen antitrust oversight in health care without immediate operational changes.
On Citizens: If the study leads to recommendations and subsequent actions, it could lower health care costs, improve access to affordable providers, and reduce industry consolidation, benefiting consumers through more competitive markets. No direct international relations impacts are anticipated, as the focus is domestic health care.
Broader Effects: The study might highlight barriers to transparency (e.g., via gag clauses), potentially encouraging policies that empower patients with better information on costs and quality.

Main Stakeholders Affected

Health Insurers and Plan Administrators: Subject to scrutiny of their contract practices, which could face future restrictions.
Health Care Providers (e.g., hospitals, doctors): Impacted by clauses that limit their negotiating power or network inclusion; the study may affect how they contract with insurers.
Consumers and Enrollees: Primary beneficiaries if competition increases, leading to lower prices and better access.
Federal Agencies: GAO (leads study), FTC, and DOJ (provide input and face resource assessments).
Congressional Committees: Receive the report and may act on recommendations, influencing health policy.

Notable Legal, Constitutional, or Political Implications

Legal: Reinforces federal antitrust laws (e.g., Sherman Act) in the health sector by prompting evidence-based evaluation, without challenging existing contract freedoms. Definitions clarify terms for enforcement but do not create new liabilities.
Constitutional: No apparent issues; the bill aligns with Congress's commerce clause authority over interstate health care markets and GAO's role in oversight.
Political: Could spark bipartisan interest in curbing health care costs and consolidation, potentially leading to follow-on legislation. It highlights tensions between industry protections and consumer interests, but remains neutral by focusing on study rather than mandates.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Spartz, Victoria [R-IN-5]

Recent Actions

2025-04-24: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-04-24: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-04-24: Introduced in House
2025-04-24: Introduced in House

Bill Versions

Addressing Anti-Competitive Health Care Contract Clauses Act — issued 2025-04-24 — PDF (6 pages)